Hoechst Pakistan Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0021801011
PKR
3,444.54
231.54 (7.21%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 29.65

 
2

Low Debt Company with Strong Long Term Fundamental Strength

 
3

With ROE of 28.2, it has a attractive valuation with a 4.3 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PKR 36,921 Million (Mid Cap)

stock-summary
P/E

17.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.88%

stock-summary
Debt Equity

-0.17

stock-summary
Return on Equity

35.39%

stock-summary
Price to Book

4.51

Revenue and Profits:
Net Sales:
6,373 Million
(Quarterly Results - Dec 2025)
Net Profit:
689 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.68%
0%
10.68%
6 Months
29.83%
0%
29.83%
1 Year
137.72%
0%
137.72%
2 Years
355.63%
0%
355.63%
3 Years
301.93%
0%
301.93%
4 Years
258.81%
0%
258.81%
5 Years
310.06%
0%
310.06%

Hoechst Pakistan Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
17.02%
EBIT Growth (5y)
35.38%
EBIT to Interest (avg)
29.65
Debt to EBITDA (avg)
0.10
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
3.87
Tax Ratio
42.86%
Dividend Payout Ratio
79.82%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
44.09%
ROE (avg)
15.90%

Valuation key factors

Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
5.64
EV to EBIT
7.67
EV to EBITDA
7.20
EV to Capital Employed
8.56
EV to Sales
1.25
PEG Ratio
0.43
Dividend Yield
2.65%
ROCE (Latest)
111.56%
ROE (Latest)
33.45%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -23.12% vs -4.94% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -20.54% vs 9.85% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,372.60",
          "val2": "8,289.30",
          "chgp": "-23.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,310.50",
          "val2": "1,760.60",
          "chgp": "-25.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "23.40",
          "val2": "18.30",
          "chgp": "27.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "689.40",
          "val2": "867.60",
          "chgp": "-20.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "189.60%",
          "val2": "201.90%",
          "chgp": "-1.23%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 15.73% vs 25.17% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 56.16% vs 414.72% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "30,955.40",
          "val2": "26,747.80",
          "chgp": "15.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6,053.50",
          "val2": "3,359.80",
          "chgp": "80.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "99.90",
          "val2": "144.50",
          "chgp": "-30.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "18.90",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,900.10",
          "val2": "1,857.10",
          "chgp": "56.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "184.10%",
          "val2": "114.10%",
          "chgp": "7.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
6,372.60
8,289.30
-23.12%
Operating Profit (PBDIT) excl Other Income
1,310.50
1,760.60
-25.57%
Interest
23.40
18.30
27.87%
Exceptional Items
0.00
0.00
Consolidate Net Profit
689.40
867.60
-20.54%
Operating Profit Margin (Excl OI)
189.60%
201.90%
-1.23%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -23.12% vs -4.94% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -20.54% vs 9.85% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
30,955.40
26,747.80
15.73%
Operating Profit (PBDIT) excl Other Income
6,053.50
3,359.80
80.17%
Interest
99.90
144.50
-30.87%
Exceptional Items
0.00
18.90
-100.00%
Consolidate Net Profit
2,900.10
1,857.10
56.16%
Operating Profit Margin (Excl OI)
184.10%
114.10%
7.00%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 15.73% vs 25.17% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 56.16% vs 414.72% in Dec 2024

stock-summaryCompany CV
About Hoechst Pakistan Ltd. stock-summary
stock-summary
Hoechst Pakistan Ltd.
Pharmaceuticals & Biotechnology
Sanofi-Aventis Pakistan Limited (Sanofi) is a Pakistan-based company, which is engaged in the manufacturing and selling of pharmaceutical and consumer products. The Company's segment is manufacturing and selling of pharmaceutical and consumer products. The Company offers medicines, consumer healthcare products, generics and animal health products. Its products include oral anti-diabetics, such as Amaryl and Amaryl M, Daonil and Daonil - M, and Neodipar; insulins, such as Lantus, Apidra and SoloSTAR; cancer, such as Jevtana, Taxotere, Eloxatin and Fludara; pain management, such as No-Spa, Gardan, Muscoril and Profenid; allergy management, such as Telfast, Avil, Nasacort, Phenergan and Avomine; cough and cold, such as Rhinathiol and Tixylix; sleep disorders, such as Stilnox; emergency care, such as Haemaccel; cardiology, such as Plavix, CoPlavix, Aprovel, Co Aprovel, Clexane, Tritace, Co Tritacem and Winstor, and antibiotics, such as Tarivid, Claforan, Aventriax and Rulid.
Company Coordinates stock-summary
Company Details
Plot No. 23, Sector No. 22, Korangi Industrial Area, KARACHI None : 74900
stock-summary
Tel: 92 21 35060221
stock-summary
Registrar Details